Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Raymond James & Associates

Raymond James & Associates raised its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 248,348 shares of the medical research company’s stock after purchasing an additional 4,660 shares during the period. Raymond James & Associates’ holdings in Charles River Laboratories International were worth $67,290,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. VisionPoint Advisory Group LLC boosted its holdings in Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $37,000. Operose Advisors LLC acquired a new stake in Charles River Laboratories International during the 3rd quarter worth $42,000. Venturi Wealth Management LLC raised its stake in Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after acquiring an additional 112 shares in the last quarter. Finally, Brown Brothers Harriman & Co. lifted its position in Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 95 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Citigroup upped their target price on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Evercore ISI raised their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. UBS Group boosted their price target on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Finally, Guggenheim cut Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Price Performance

CRL stock traded up $3.58 on Friday, reaching $233.47. 466,193 shares of the company’s stock were exchanged, compared to its average volume of 482,082. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. The stock has a fifty day moving average of $252.23 and a 200-day moving average of $223.97. The firm has a market cap of $12.03 billion, a PE ratio of 25.35, a P/E/G ratio of 1.80 and a beta of 1.44.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. Charles River Laboratories International’s quarterly revenue was down 7.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.98 earnings per share. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Insider Activity

In related news, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now owns 22,879 shares in the company, valued at approximately $5,685,431.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares in the company, valued at $626,155.20. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock worth $3,693,663 over the last three months. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).